Valuation: ImmunoCellular Therapeutics Ltd

Market Cap 92.85M 80.19M 75.45M 68.57M 129M 8.9B 131M 885M 347M 4.45B 349M 341M 14.82B P/E 2020 *
-
P/E 2021 -3.82x
Enterprise Value 94.18M 81.34M 76.53M 69.56M 131M 9.02B 133M 898M 352M 4.51B 354M 346M 15.03B EV / Sales 2020 *
-
EV / Sales 2021 -
Free-Float
-
Yield 2020 *
-
Yield 2021 -

Financials

2020 2021
Net sales - -
Net income -1.94M -1.67M -1.57M -1.43M -2.69M -186M -2.73M -18.47M -7.24M -92.84M -7.27M -7.12M -309M -5.15M -4.45M -4.18M -3.8M -7.15M -493M -7.26M -49.08M -19.24M -247M -19.33M -18.91M -822M
Net Debt -263K -227K -214K -194K -365K -25.2M -371K -2.51M -982K -12.6M -987K -966K -41.98M 1.33M 1.15M 1.08M 982K 1.85M 127M 1.87M 12.68M 4.97M 63.74M 4.99M 4.89M 212M
Logo ImmunoCellular Therapeutics Ltd
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.
Employees
-
Sector
-